All grade 3 or higher adverse events at least possibly treatment related based on the starting dose of 30 or 25 mg
| Toxicity type, n . | 30 mg (n = 24) . | 25 mg (n = 12) . | ||||
|---|---|---|---|---|---|---|
| Grade 3 . | Grade 4 . | Total (%) . | Grade 3 . | Grade 4 . | Total (%) . | |
| Platelets | 10 | 6 | 16 (67) | 5 | 3 | 8 (67) |
| Hemoglobin | 5 | 2 | 7 (29) | 3 | 0 | 3 (25) |
| Neutrophils | 5 | 2 | 7 (29) | 4 | 2 | 6 (50) |
| Leukocytes | 3 | 1 | 4 (17) | 3 | 1 | 4 (33) |
| Fatigue | 2 | 0 | 2 (8) | 2 | 0 | 2 (17) |
| Syncope | 2 | 0 | 2 (8) | 0 | 0 | 0 |
| Hypophosphatemia | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Lower GI/hemorrhage NOS | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Nonneuropathic generalized weakness | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Bilirubin | 0 | 0 | 0 | 1 | 0 | 1 (8) |
| Total | 32 | 12 | 44 | 18 | 0 | 24 |
| Toxicity type, n . | 30 mg (n = 24) . | 25 mg (n = 12) . | ||||
|---|---|---|---|---|---|---|
| Grade 3 . | Grade 4 . | Total (%) . | Grade 3 . | Grade 4 . | Total (%) . | |
| Platelets | 10 | 6 | 16 (67) | 5 | 3 | 8 (67) |
| Hemoglobin | 5 | 2 | 7 (29) | 3 | 0 | 3 (25) |
| Neutrophils | 5 | 2 | 7 (29) | 4 | 2 | 6 (50) |
| Leukocytes | 3 | 1 | 4 (17) | 3 | 1 | 4 (33) |
| Fatigue | 2 | 0 | 2 (8) | 2 | 0 | 2 (17) |
| Syncope | 2 | 0 | 2 (8) | 0 | 0 | 0 |
| Hypophosphatemia | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Lower GI/hemorrhage NOS | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Nonneuropathic generalized weakness | 1 | 0 | 1 (4) | 0 | 0 | 0 |
| Bilirubin | 0 | 0 | 0 | 1 | 0 | 1 (8) |
| Total | 32 | 12 | 44 | 18 | 0 | 24 |
NOS indicates not otherwise specified.